# 针基活检枪市场

> 基于针头的活检枪市场研究报告按类型（全自动活检枪、半自动活检枪、手动活检枪）、按最终用途（医院、诊断实验室、研究机构、门诊手术中心）、按产品配置（一次性、可重复使用）、按针头尺寸（细规、 中规、大规）以及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.32%
- **2024:** $ 2.14 Billion
- **2025:** $ 2.3 Billion
- **2035:** $ 4.65 Billion
- **Key Players:** Becton Dickinson and Company (US), Boston Scientific Corporation (US), Medtronic plc (IE), Hologic, Inc. (US), Cook Medical Incorporated (US), Terumo Corporation (JP), Smith & Nephew plc (GB), Stryker Corporation (US), C.R. Bard, Inc. (US)

**Report ID:** MRFR/HC/36922-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** May 21, 2026

**URL:** https://www.marketresearchfuture.com/reports/needle-based-biopsy-gun-market-38903

---

## Market Summary

## **Needle-Based Biopsy Gun Market Overview**

As per MRFR analysis, the Needle Based Biopsy Gun Market Size was estimated at 2.14 (USD Billion) in 2024. The Needle Based Biopsy Gun Market Industry is expected to grow from 2.29 (USD Billion) in 2025 to 4.33 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 7.32% during the forecast period (2025 - 2034).

**Key Needle-Based Biopsy Gun Market Trends Highlighted**

The Global Market For Needle-Based Biopsy Guns that utilize needles is primarily driven by the presence of prominent factors that have a positive impact on its growth. With the increasing occurrence of patients with different cancers and other diseases that require accurate diagnosis, there is a great demand for biopsy. Many patients prefer nowadays minimally invasive procedures, which lead to shorter recovery periods and less physical pain.

In addition, the consciousness of sophisticated masses on the importance of timely treatment of disease makes the market move forward at an ever-increasing pace where patients always look for efficient services. The opportunities in the market for needle-based biopsy guns are great especially where there is continuing advancement and innovations on the medical equipment.

Again, with patients where the healthcare industry is in the transitioning phase, growth possibilities with the increasing need for advanced diagnostics. As demand for needle-based biopsy devices across a variety of healthcare providers rises, collaborations between device manufacturers and healthcare organizations may also improve the availability and uptake of these technologies in clinical settings. There has been a growing trend in recent years towards the utilization of imaging modalities such as ultrasound and CT for guidance during biopsy procedures, which is becoming more routine.

This advancement not only enhances the precision of biopsies but also improves patient safety. Moreover, the growing shift towards outpatient procedures aligns with the convenience and efficiency offered by needle-based biopsy techniques. Telemedicine's integration into healthcare systems is also influencing how patients access biopsy services, making it easier for specialists to review cases remotely. As the healthcare landscape evolves, these trends continue to emerge, guiding the trajectory of the Needle-Based Biopsy Gun Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Needle-Based Biopsy Gun Market Drivers**

### Increasing Incidence of Cancer

One of the most significant drivers contributing to the growth of the Needle-Based Biopsy Gun Market Industry is the increasing incidence of cancer worldwide. As cancer rates continue to rise due to factors such as aging populations, lifestyle changes, and environmental influences, the demand for effective diagnostic tools, such as needle-based biopsy guns, is becoming increasingly pronounced.

These devices allow for minimally invasive sampling of tissues, which is critical in the early diagnosis and management of various types of cancer.The ability to obtain precise tissue samples significantly aids healthcare professionals in determining the best treatment options, thus positively impacting patient outcomes. As the medical community shifts its focus toward early detection and intervention in cancer cases, the adoption of advanced diagnostic equipment, including needle-based biopsy guns, is expected to escalate.

Furthermore, an increase in awareness and advocacy surrounding cancer screenings is propelling healthcare systems to implement more efficient diagnostic procedures to meet this heightened demand.As healthcare providers strive to utilize technologies that enhance accuracy and reduce patient discomfort, needle-based biopsy guns will play an integral role in the cancer diagnostic landscape.

Innovations in this field, such as enhanced needle designs and automation features in biopsy guns, also contribute to the appeal of these devices. By making biopsies less painful and more precise, these advancements are further solidifying the position of needle-based biopsy guns as essential tools in oncology practices.

### Technological Advancements in Biopsy Devices

The ongoing technological advancements in biopsy devices are significantly influencing the growth of the Needle-Based Biopsy Gun Market Industry. Innovations such as improved imaging techniques, automated systems, and advanced needle designs lead to better performance and lower complications. As manufacturers integrate new technologies into needle-based biopsy guns, the efficiency and reliability of these devices enhance diagnostic capabilities.

### Rising Preference for Minimally Invasive Procedures

The rising preference for minimally invasive procedures is another critical driver for the Needle-Based Biopsy Gun Market Industry. Patients and healthcare providers alike are increasingly opting for less invasive methods due to the associated benefits, such as reduced recovery times, lower risk of complications, and less postoperative pain. As healthcare providers adapt to this trend by incorporating needle-based biopsy guns into their practice, the market is poised for growth unmatched by traditional diagnostic methods.

## **Needle-Based Biopsy Gun Market Segment Insights:**

### **Needle-Based Biopsy Gun Market Type Insights  **

The Needle-Based Biopsy Gun Market is currently experiencing steady growth, projected at a value of 1.86 USD Billion in 2023, and anticipated to grow significantly by 2032. This market can be divided into three main types: Fully Automatic Biopsy Guns, Semi-Automatic Biopsy Guns, and Manual Biopsy Guns.

The Fully Automatic Biopsy Guns held a market valuation of 0.8 USD Billion in 2023 and are forecasted to reach 1.5 USD Billion by 2032, making them a dominant player in the industry. The effectiveness, precision, and ease of operation offered by these guns make them highly favored among healthcare professionals, thereby driving their adoption and solidifying their majority holding in the market landscape.

In contrast, Semi-Automatic Biopsy Guns, with a valuation of 0.6 USD Billion in 2023, are also witnessing growth and are expected to reach 1.1 USD Billion by 2032. This segment is significant because it combines user control with automation, allowing for a balanced approach that appeals to various practitioners and settings, thus promoting its continued relevance in the marketplace.

Manual Biopsy Guns, while having a lower market value of 0.46 USD Billion in 2023 with expectations of growing to 0.9 USD Billion in 2032, represent the traditional method of biopsy collection. This type remains in use due to its simplicity and lower costs, though it lacks the efficacy of its automated counterparts.

Overall, the segmentation of the Needle-Based Biopsy Gun Market highlights a trend toward automated solutions, with the Fully Automatic Biopsy Guns segment dominating due to their enhanced accuracy and efficiency. The growing demand for advanced diagnostic techniques in the healthcare sector significantly contributes to market growth. Furthermore, innovations in technology and increasing awareness regarding early disease diagnosis serve as growth drivers for this industry.

However, challenges such as high costs associated with advanced equipment and the need for skilled professionals may pose threats to market expansion. Nevertheless, the potential opportunities for market players lie in the ongoing development of minimally invasive procedures and the increasing prevalence of diseases requiring biopsies.

As the demand for effective and precise biopsy tools continues to rise, understanding the dynamics of the Needle-Based Biopsy Gun Market segmentation becomes increasingly important for stakeholders in strategizing their market presence and addressing the needs of healthcare providers.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Needle-Based Biopsy Gun Market End-Use Insights  **

The Needle-Based Biopsy Gun Market is expected to see robust growth driven by its application across various end-use sectors. By 2023, the market was valued at 1.86 billion USD and projects substantial expansion over the ensuing years. Hospitals play a crucial role in this market, being primary sites for diagnostics and treatment. Diagnostic laboratories are significant contributors as well, primarily due to the increasing demand for accurate and rapid testing methods.

Research institutions drive innovation, enhancing the market landscape with advanced technologies in biopsy procedures.Meanwhile, ambulatory surgical centers are becoming increasingly important as they offer cost-effective solutions and convenience, attracting more patients seeking outpatient services.

The diversification across these end uses not only signifies the demand for needle-based biopsy guns but also underscores the advancements in minimally invasive procedures, addressing the needs of healthcare providers and patients alike. As the market continues to evolve, an emphasis on technological developments and strategic collaborations will present avenues for growth, making it essential to monitor the Needle-Based Biopsy Gun Market statistics for emerging trends and opportunities.

**Needle-Based Biopsy Gun Market Product Configuration Insights  **

The Needle-Based Biopsy Gun Market reached a valuation of 1.86 billion USD by 2023, highlighting a significant growth trajectory. Within this market, the Product Configuration segment is categorized into options like Single Use and Reusable models. Single-use configurations are essential due to their convenience and reduced risk of contamination, thus enhancing patient safety during procedures.

Meanwhile, Reusable devices play a pivotal role by offering cost-effective solutions, particularly in high-volume settings where sustainability is a growing concern.The Needle-Based Biopsy Gun Market revenue demonstrates a strong emphasis on these configurations, combating challenges such as adoption barriers and device reprocessing logistics.

As healthcare providers seek more effective diagnostic tools, market growth is driven by technological advancements, increased awareness of biopsy procedures, and rising incidences of diseases requiring biopsies. Furthermore, opportunities in emerging markets are expected further to influence the Needle-Based Biopsy Gun Market statistics, encouraging innovations and customization in product offerings.

### **Needle-Based Biopsy Gun Market Needle Size Insights  **

The Needle Size segment of the Needle-Based Biopsy Gun Market plays a pivotal role in the market's dynamics, reflecting diverse clinical applications and preferences. In 2023, the overall market will be valued at 1.86 billion USD, showcasing substantial growth potential as it progresses towards an estimated value of 3.5 billion USD by 2032. Within this segment, Fine Gauge needles are often preferred for their minimal discomfort and precision, making them ideal for sensitive tissue sampling.

On the other hand, Medium Gauge needles strike a balance between tissue sampling efficiency and patient comfort, while Large Gauge needles dominate in scenarios requiring deeper or larger tissue samples due to their robustness.The various needle sizes are not only essential for optimizing biopsy procedures but also significantly influence patient outcomes, demonstrating the importance of customization in the medical field.

The Needle-Based Biopsy Gun Market segmentation reflects these trends, showing increasing demand for different needle sizes driven by advancements in healthcare and a growing patient population. As the market evolves, continuous innovations will drive its expansion, positioning Needle Size as a crucial factor influencing the overall market growth.

**Needle-Based Biopsy Gun Market Regional Insights  **

The Needle-Based Biopsy Gun Market exhibited a significant valuation of 1.86 USD Billion in 2023, with expected growth reaching 3.5 USD Billion by 2032, representing a promising trajectory. Within the regional landscape, North America emerged as a dominant force, holding a substantial market value of 0.88 USD Billion in 2023, projected to rise to 1.58 USD Billion by 2032, showcasing the region's majority holding in the overall market.

Europe, with a current valuation of 0.56 USD Billion, also reflects robust growth potential, expected to reach 1.02 USD Billion in the coming years.In the Asia-Pacific region, the market was valued at 0.3 USD Billion in 2023 and is anticipated to see an increase to 0.55 USD Billion, highlighting a growing interest in advanced medical technologies.

South America and Middle-East  Africa are comparatively smaller markets, each starting at 0.06 USD Billion in 2023, with projected values of 0.1 USD Billion and 0.15 USD Billion, respectively. Despite being the least dominant, these regions present opportunities for expansion, driven by increasing healthcare advancements and rising awareness about needle-based biopsy techniques.The segmentation of the Needle-Based Biopsy Gun Market indicates a landscape of diverse growth possibilities across regions, influenced by market trends and rising demand for minimally invasive procedures.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Needle-Based Biopsy Gun Market Key Players and Competitive Insights:**

The Needle-Based Biopsy Gun Market is a crucial segment of the medical device industry, particularly within the realm of minimally invasive diagnostics. As the demand for precise and efficient diagnostic tools continues to rise, competitive dynamics are becoming increasingly pivotal in shaping this market.

Key players are focusing on advanced technologies, innovation, and strategic partnerships to establish a formidable market presence. The interplay of various factors, such as regulatory landscapes, research and development investments, and shifting healthcare trends, is setting the stage for intense competition among manufacturers. Companies are actively pursuing ways to differentiate their offerings through enhanced safety features, increased mobility, and user-friendly designs. Moreover, market players are engaging in collaborations and acquisitions to expand their capabilities and reach new demographics, further intensifying the race for market share.

Stryker, a foremost player in the Needle-Based Biopsy Gun Market, has established a strong reputation due to its commitment to quality and innovation. The company's strength lies in its extensive range of products designed specifically for precision and ease of use during biopsy procedures. By prioritizing user experience, Stryker has successfully provided healthcare professionals with reliable tools that enhance procedural efficiency and patient outcomes. The integration of advanced technologies in their needle-based biopsy guns underscores Stryker's dedication to remaining at the forefront of the industry.

Additionally, Stryker's robust distribution network allows it to maintain a significant presence in various regions, making its products readily available to a wide array of healthcare facilities. This proactive approach, focused on innovation and accessibility, solidifies Stryker's position as a leading competitor within the market.

Hologic is another significant entity in the Needle-Based Biopsy Gun Market, known for its dedication to women's health and breast cancer diagnostics. The company offers a range of needle-based biopsy solutions designed to address the specific needs of patients and healthcare providers alike. Hologic's strengths are rooted in its rigorous research and development efforts that result in cutting-edge technologies, enhancing the precision and reliability of biopsy procedures.

Their commitment to clinical education and support further empowers medical professionals in utilizing biopsy tools effectively. Hologic's initiatives to improve patient comfort and outcomes demonstrate its understanding of the industry's evolving demands. As a result, Hologic continues to expand its market reach while maintaining a firm foothold in the competitive landscape of needle-based biopsy guns.

**Key Companies in the Needle-Based Biopsy Gun Market Include:**

- Stryker
- Hologic
- Intuitive Surgical
- R. Bard
- Teleflex
- MediGel
- Philips Healthcare
- Angiodynamics
- Johnson and  Johnson
- GE Healthcare
- Boston Scientific
- Merit Medical
- Covidien
- Siemens Healthineers
- **[Medtronic](https://www.medtronic.com/en-us/healthcare-professionals/products.html)**

### Needle Based Biopsy Gun Industry Developments

- **Q2 2024: Argon Medical Devices Announces FDA Clearance of SuperCore Advantage Biopsy Instrument** Argon Medical Devices received FDA clearance for its SuperCore Advantage Biopsy Instrument, a new needle-based biopsy gun designed for soft tissue biopsies. The device aims to improve sample quality and procedural efficiency.
- **Q1 2024: INRAD, Inc. Launches New Core Needle Biopsy Device for Breast and Prostate Applications** INRAD, Inc. announced the commercial launch of its latest core needle biopsy device, targeting breast and prostate tissue sampling. The product is now available to hospitals and diagnostic centers in the United States.
- **Q2 2024: Becton Dickinson Receives CE Mark for BD UltraCore Biopsy Device** Becton Dickinson (BD) received CE Mark approval for its BD UltraCore Biopsy Device, allowing the company to market the needle-based biopsy gun in the European Union. The device is designed for minimally invasive tissue sampling.
- **Q3 2024: Hologic Announces FDA Clearance for Brevera Breast Biopsy System with Needle-Based Gun Technology** Hologic received FDA clearance for its Brevera Breast Biopsy System, which incorporates advanced needle-based gun technology for real-time tissue acquisition and imaging during breast biopsies.
- **Q2 2024: Merit Medical Launches Temno Evolution Biopsy Device in the U.S.** Merit Medical Systems announced the U.S. launch of its Temno Evolution Biopsy Device, a single-use, needle-based biopsy gun designed to enhance procedural safety and sample quality.
- **Q1 2024: Boston Scientific Acquires Devicor Medical Products, Expanding Biopsy Device Portfolio** Boston Scientific completed the acquisition of Devicor Medical Products, a manufacturer of needle-based biopsy guns and related devices, to strengthen its position in the tissue sampling market.
- **Q2 2024: ConMed Corporation Announces Partnership with MedTech Innovations for Needle Biopsy Device Distribution** ConMed Corporation entered into a distribution partnership with MedTech Innovations to expand the reach of its needle-based biopsy guns in North America and select international markets.
- **Q3 2024: Henry Schein Launches New Line of Disposable Needle Biopsy Guns** Henry Schein introduced a new line of disposable needle biopsy guns aimed at reducing infection risk and improving procedural efficiency in outpatient and hospital settings.
- **Q2 2024: Coloplast Receives FDA 510(k) Clearance for Core Needle Biopsy System** Coloplast announced it has received FDA 510(k) clearance for its new core needle biopsy system, enabling the company to market the device for soft tissue biopsies in the United States.
- **Q1 2024: Hologic Appoints New Vice President of Biopsy Device Division** Hologic announced the appointment of a new Vice President to lead its Biopsy Device Division, overseeing the development and commercialization of needle-based biopsy guns and related products.
- **Q2 2024: Becton Dickinson Opens New Manufacturing Facility for Biopsy Devices in Ireland** Becton Dickinson inaugurated a new manufacturing facility in Ireland dedicated to the production of needle-based biopsy guns, aiming to meet growing global demand for minimally invasive diagnostic tools.
- **Q3 2024: Argon Medical Devices Secures Distribution Agreement with MedSupply for Asia-Pacific Region** Argon Medical Devices signed a distribution agreement with MedSupply to expand the availability of its needle-based biopsy guns across the Asia-Pacific region.

## **Needle-Based Biopsy Gun Market Segmentation Insights**

### **Needle-Based Biopsy Gun Market Type Outlook**

- Fully Automatic Biopsy Guns
- Semi-Automatic Biopsy Guns
- [Manual Biopsy Guns](https://www.bd.com/en-us/products-and-solutions/products/product-families/mission-disposable-core-biopsy-instrument)

**Needle-Based Biopsy Gun Market End-Use Outlook**

- Hospitals
- Diagnostic Laboratories
- Research Institutions
- Ambulatory Surgical Centers

**Needle-Based Biopsy Gun Market Product Configuration Outlook**

- Single-Use
- Reusable

**Needle-Based Biopsy Gun Market Needle Size Outlook**

- Fine Gauge
- Medium Gauge
- Large Gauge

**Needle-Based Biopsy Gun Market Regional Outlook**

- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa

## Market Drivers

### 癌症发病率上升

针头活检枪市场受到全球癌症发病率上升的显著影响。随着癌症发病率的持续上升，准确及时的诊断变得至关重要。针头活检对于获取组织样本以进行组织病理学检查至关重要，这对癌症的诊断和治疗计划至关重要。最近的统计数据显示，到2040年，全球癌症负担预计将达到2950万新病例，突显了对有效诊断工具的迫切需求。对癌症诊断的日益增长的需求可能会推动针头活检枪市场的发展，因为医疗服务提供者寻求可靠和高效的组织取样方法。因此，针头活检枪市场有望实现显著增长，推动因素是对癌症护理中早期检测和干预的日益需求。

### 监管支持和报销政策

针头活检枪市场受益于有利的监管支持和报销政策，这些政策鼓励先进医疗技术的采用。各国政府和卫生组织越来越认识到早期诊断和治疗的重要性，从而建立了支持创新医疗设备的框架。针对针头活检程序的增强报销政策可能会激励医疗服务提供者采用这些技术。市场数据显示，拥有健全报销结构的地区在针头活检枪市场上正经历更快的增长。随着医疗系统的不断发展，监管支持与市场需求的对接预计将促进针头活检枪的增长环境，最终改善患者获得必要诊断服务的机会。

### 对微创手术需求的上升

针头活检枪市场受到微创手术需求上升的显著影响。患者和医疗服务提供者越来越倾向于减少恢复时间和降低手术风险的技术。与传统外科活检相比，针头活检的侵入性较小，符合这一趋势。市场数据显示，门诊手术的偏好正在上升，每年进行的针头活检数量显著增加。这一转变预计将推动针头活检枪市场的增长，因为这些设备对于有效进行此类手术至关重要。随着医疗系统继续优先考虑患者安全和舒适，针头活检枪的需求预计将扩大，反映出向更少侵入性医疗干预的更广泛趋势。

### 关注以患者为中心的设计

针头活检枪市场正朝着以患者为中心的设计转变，优先考虑用户体验和舒适度。制造商越来越关注人体工程学和易用性，这对医疗服务提供者和患者都至关重要。减少在手术过程中疼痛和焦虑的增强设计正成为产品开发的重点。市场分析表明，具有改进的以患者为中心的特征的设备可能会获得竞争优势，因为它们与医疗保健中日益重视患者满意度的趋势相一致。此外，随着医疗服务提供者寻求改善其服务，满足患者需求的创新针头活检枪的需求预计将上升。这一趋势不仅提升了整体患者体验，还促进了更好的临床结果，从而推动市场增长。

### 基于针的活检枪的技术进步

针头活检枪市场正在经历技术进步的激增，这些进步提高了活检程序的精确性和效率。自动化针头引导系统和实时成像集成等创新正变得越来越普遍。这些进步不仅提高了组织取样的准确性，还降低了并发症的风险。根据最近的数据，针头活检枪市场预计在未来五年内将以约6.5%的复合年增长率增长。这一增长主要是由于医疗环境中对先进技术的日益采用，旨在改善患者结果并简化临床工作流程。随着医疗提供者寻求采用最新技术，对复杂针头活检枪的需求可能会增加，从而进一步推动市场发展。

## Future Outlook

基于针的活检枪市场预计将在2024年至2035年间以7.32%的年均增长率增长，推动因素包括技术进步、癌症发病率上升以及对微创手术需求的增加。

**New opportunities:**

- 先进成像集成的开发，以实现精确定位

到2035年，市场预计将实现强劲增长，巩固其在医疗保健行业中的地位。

## Segment Insights

### 按类型：全自动活检枪（最大）与半自动活检枪（增长最快）

针基活检枪市场细分中，完全自动活检枪占据主导地位，拥有最大的市场份额。其先进的技术和在精确操作中的高效性使其成为医疗服务提供者的首选。相比之下，半自动活检枪正在获得关注，吸引那些寻求自动化与手动控制之间平衡的用户，从而促进了其快速的市场增长。

活检枪：全自动（主流）与半自动（新兴）

全自动活检枪以其易用性和高效率为特征，成为许多临床环境中的首选。这些设备减少了手动干预，从而提高了准确性和更快的操作时间。同时，半自动活检枪作为一种显著的替代方案，正在崭露头角，为医疗专业人员提供了一定的控制权，同时仍然提供一些自动化功能。这种组合迎合了从业者的多样化偏好，推动了它们在市场上的增长，因为它们适应了各种程序要求。

### 按最终用途：医院（最大）与诊断实验室（增长最快）

在基于针的活检枪市场中，医院占据了最大的份额，这得益于其高患者流量和先进的基础设施，能够支持复杂的程序。诊断实验室紧随其后，在提供快速诊断服务方面发挥着重要作用，使其在这一领域至关重要。研究机构和门诊手术中心的市场份额较小，但在专门程序和门诊服务中至关重要。

医院（主导）与诊断实验室（新兴）

医院是针基活检枪市场的主导部分，因为它们拥有广泛的医疗设施和大量的活检程序。它们专注于整合先进技术，并保持广泛的活检枪种类，以满足不同患者的需求。另一方面，诊断实验室作为一个关键部分，反映出对准确和及时诊断的需求增加，通常采用尖端的活检技术。这一转变得到了癌症和其他需要活检评估的疾病发病率上升的支持，使诊断实验室成为医疗生态系统中不断发展和不可或缺的一部分。

### 按产品配置：一次性（最大）与可重复使用（增长最快）

基于针的活检枪市场分为一次性和可重复使用的产品配置。由于其便利性和降低交叉污染的风险，一次性设备在这一细分市场中占主导地位。它们在卫生至关重要的临床环境中尤其受到青睐。因此，一次性设备占据了最大的市场份额，推动因素包括日益严格的患者安全法规和医疗服务提供者对程序简化的重视。相反，可重复使用的设备正在获得关注，虽然占比较小，但增长迅速。这一激增主要归因于其成本效益和可持续性，吸引了希望减少废物和经济支出的机构。
产品配置细分市场的增长趋势表明，尽管一次性设备继续作为即时程序的首选，但可重复使用设备正经历显著转变。对一次性产品相关环境影响的日益关注促使医疗服务提供者采用可重复使用的解决方案，从而推动其市场增长。此外，灭菌技术的进步增强了可重复使用设备的吸引力。随着医疗系统的不断发展，一次性便利性与可重复使用选项的经济优势之间的平衡将塑造未来在基于针的活检枪市场中的采购决策。

一次性（主导）与可重复使用（新兴）

一次性设备在基于针的活检枪市场中以其为每个程序提供无菌、即用解决方案的能力而著称，消除了与再处理相关的复杂性。它们在患者周转率高、效率至关重要的医院和门诊诊所中被广泛采用。一次性设备的主导地位受到严格的监管标准和对患者安全的高度关注的推动。另一方面，可重复使用设备代表了一个新兴细分市场，展示了有效灭菌和维护的创新。可重复使用设备的吸引力在于其可持续性和长期成本节约，受到努力遵循环保实践的医疗机构的关注，同时保持运营效率。

### 按针头大小：细规（最大）与大规（增长最快）

在基于针的活检枪市场中，针头尺寸细分展示了细针、中等针和大针之间的多样分布。细针因其增强的精确度而占据了最大的市场份额，减少了对患者的创伤和相关并发症。这使得它们在专注于微创技术的医疗服务提供者中占据了有利地位，巩固了它们在当代活检程序中的重要角色。

相反，大针正在成为该市场中增长最快的细分市场，推动这一趋势的是对复杂诊断中更大组织样本的需求日益增长。它们提供更大组织核心的能力提高了病理分析的准确性，使其在寻求可靠和全面诊断方法的肿瘤学家和放射科医生中越来越受欢迎，随着治疗的演变。

细规（主导）与大规（新兴）

细针段以其在活检程序中的广泛接受度为特征，因其能够减少患者不适感并提供准确结果而受到青睐。医疗专业人员越来越倾向于选择这些针头，因为它们具有侵入性较小和恢复时间缩短的优点，从而巩固了它们在市场上的主导地位。相比之下，大针头被标记为新兴选择，受到活检技术进步的推动，优先考虑获取更大组织样本。这些针头适用于需要更广泛组织分析的专业程序，从而在诊断中开辟了一个重要的细分市场。随着临床实践的发展，这两个细分市场展现出独特的特征，以满足不同的医疗需求，影响活检领域的整体市场策略。

## Regional Market Share Analysis

### 北美：创新市场的领导者

北美是基于针的活检枪的最大市场，约占全球市场份额的45%。增长的驱动因素包括先进的医疗基础设施、癌症的日益普遍以及对微创手术的需求上升。来自FDA等机构的监管支持进一步促进了市场扩展，确保医疗设备的安全性和有效性。
美国是主要贡献者，在研发方面进行了大量投资，并且拥有贝克顿·迪金森公司和波士顿科学公司等关键企业的强大存在。加拿大也发挥着重要作用，专注于改善医疗服务的可及性和技术的采用。竞争格局以创新和领先公司之间的战略合作为特征。

### 欧洲：具有增长潜力的新兴市场

欧洲是基于针的活检枪的第二大市场，约占全球市场份额的30%。该地区受益于严格的监管框架，确保高质量的医疗设备，同时提高了对早期癌症检测的认识。德国和法国等国在推动先进诊断工具方面处于领先地位，拥有有利的医疗政策。
德国作为关键参与者，强调医疗技术的研究与开发。竞争格局包括美敦力和霍洛吉克等主要公司，这些公司正在积极扩展其产品供应。欧洲市场还见证了医疗服务提供者与制造商之间的合作，以提升服务交付和患者结果。

### 亚太地区：快速增长的医疗保健行业

亚太地区的基于针的活检枪市场正在快速增长，驱动因素包括医疗支出的增加和癌症发病率的上升。该地区约占全球市场份额的20%，中国和印度等国处于领先地位。政府旨在改善医疗基础设施和获取先进医疗技术的举措是重要的增长驱动因素。
中国是该地区最大的市场，得益于庞大的人口和对诊断程序日益增长的需求。印度紧随其后，越来越关注医疗创新。竞争格局中既有本地企业也有国际企业，包括泰尔茂公司和库克医疗公司，他们正在扩大在活检解决方案市场的存在，以满足日益增长的需求。

### 中东和非洲：具有潜力的未开发市场

中东和非洲地区是基于针的活检枪的新兴市场，目前约占全球市场份额的5%。增长主要受医疗投资增加和慢性疾病（包括癌症）发病率上升的推动。南非和阿联酋等国正专注于提升其医疗系统，这预计将推动对先进诊断工具的需求。
南非在该地区的市场中处于领先地位，越来越多的医疗设施采用创新技术。竞争格局正在演变，本地和国际公司（包括史密斯和内夫公司及斯特莱克公司）都在寻求利用对活检解决方案日益增长的需求。随着医疗服务的可及性改善和意识的提高，该地区呈现出显著的增长机会。

## Competitive Benchmarking

基于针的活检枪市场目前的特点是动态竞争格局，受到技术进步和对微创手术需求增加的驱动。关键参与者如贝克顿·迪金森公司（美国）、波士顿科学公司（美国）和霍洛吉公司（美国）在战略上定位以利用创新并扩大市场份额。例如，贝克顿·迪金森专注于通过持续的研究和开发来增强其产品组合，而波士顿科学则强调战略合作伙伴关系以增强其技术能力。另一方面，霍洛吉则专注于区域扩张，特别是在新兴市场，这共同塑造了一个既合作又竞争的环境。

在商业策略方面，公司越来越多地本地化制造，以降低成本并提高供应链效率。基于针的活检枪市场似乎适度分散，多个参与者争夺市场份额。这种分散使得产品和创新的多样性得以实现，但像美敦力公司（爱尔兰）和库克医疗公司（美国）这样的主要参与者的集体影响力是显著的，因为他们设定了行业标准并推动技术进步。

在2025年8月，美敦力公司（爱尔兰）宣布推出一款新的基于针的活检枪，旨在提高精确度并减少患者不适。这一战略举措可能会通过满足医疗行业对以患者为中心的解决方案日益增长的需求来增强美敦力的竞争优势。这一创新产品的推出不仅强化了美敦力对推进医疗技术的承诺，还使公司在竞争对手中处于有利地位。

在2025年9月，库克医疗公司（美国）通过推出一款集成先进成像技术的下一代活检枪扩展了其产品线。这一发展表明库克医疗的战略是将尖端技术融入其产品中，从而提高诊断准确性。这种创新在一个精确性和可靠性至关重要的市场中至关重要，表明库克医疗希望通过技术差异化来保持其竞争优势。

在2025年10月，霍洛吉公司（美国）与一家领先的成像技术公司建立了战略合作伙伴关系，以增强其活检解决方案。这一合作预计将促进先进成像能力与霍洛吉活检枪的整合，从而改善手术结果。这一合作关系强调了在当前市场中战略联盟的重要性，因为公司寻求结合优势并更有效地创新。

截至2025年10月，基于针的活检枪市场正在见证数字化和人工智能整合等趋势，这些趋势正在重塑竞争动态。公司越来越关注可持续性和技术进步，以实现差异化。从基于价格的竞争转向关注创新和供应链可靠性变得越来越明显，这表明未来的竞争差异化将取决于提供卓越技术和患者结果的能力。

## Recent News & Developments

- **2024年第二季度：Argon Medical Devices宣布SuperCore Advantage活检仪获得FDA批准** Argon Medical Devices获得FDA批准，其SuperCore Advantage活检仪是一种新型针基活检枪，旨在进行软组织活检。该设备旨在提高样本质量和程序效率。
- **2024年第一季度：INRAD, Inc.推出用于乳腺和前列腺应用的新型核心针活检设备** INRAD, Inc.宣布其最新核心针活检设备的商业发布，针对乳腺和前列腺组织取样。该产品现已在美国的医院和诊断中心提供。
- **2024年第二季度：Becton Dickinson获得BD UltraCore活检设备的CE标志** Becton Dickinson (BD)获得其BD UltraCore活检设备的CE标志批准，允许该公司在欧盟市场销售该针基活检枪。该设备旨在进行微创组织取样。
- **2024年第三季度：Hologic宣布Brevera乳腺活检系统获得FDA批准，采用针基枪技术** Hologic获得FDA批准，其Brevera乳腺活检系统采用先进的针基枪技术，能够在乳腺活检过程中实时获取组织和成像。
- **2024年第二季度：Merit Medical在美国推出Temno Evolution活检设备** Merit Medical Systems宣布在美国推出其Temno Evolution活检设备，这是一种一次性针基活检枪，旨在提高程序安全性和样本质量。
- **2024年第一季度：Boston Scientific收购Devicor Medical Products，扩展活检设备组合** Boston Scientific完成对Devicor Medical Products的收购，该公司是一家针基活检枪及相关设备的制造商，以增强其在组织取样市场的地位。
- **2024年第二季度：ConMed Corporation宣布与MedTech Innovations建立针活检设备分销合作关系** ConMed Corporation与MedTech Innovations达成分销合作关系，以扩大其针基活检枪在北美和部分国际市场的覆盖范围。
- **2024年第三季度：Henry Schein推出新系列一次性针活检枪** Henry Schein推出新系列一次性针活检枪，旨在降低感染风险，提高门诊和医院环境中的程序效率。
- **2024年第二季度：Coloplast获得FDA 510(k)批准，推出核心针活检系统** Coloplast宣布其新核心针活检系统获得FDA 510(k)批准，使公司能够在美国市场销售该设备，用于软组织活检。
- **2024年第一季度：Hologic任命新副总裁负责活检设备部门** Hologic宣布任命新副总裁负责其活检设备部门，监督针基活检枪及相关产品的开发和商业化。
- **2024年第二季度：Becton Dickinson在爱尔兰开设新的活检设备制造设施** Becton Dickinson在爱尔兰启用一座新的活检设备制造设施，专注于针基活检枪的生产，旨在满足全球对微创诊断工具日益增长的需求。
- **2024年第三季度：Argon Medical Devices与MedSupply签署亚太地区分销协议** Argon Medical Devices与MedSupply签署分销协议，以扩大其针基活检枪在亚太地区的可用性。

## Report Scope

| 2024年市场规模 | 2.138（亿美元） |
| --- | --- |
| 2025年市场规模 | 2.295（亿美元） |
| 2035年市场规模 | 4.651（亿美元） |
| 复合年增长率（CAGR） | 7.32%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 亿美元 |
| 主要公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 主要市场机会 | 微创技术的进步增强了对基于针的活检枪市场解决方案的需求。 |
| 主要市场动态 | 技术进步和监管变化推动了基于针的活检枪市场的创新和竞争。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 到2035年，基于针的活检枪市场的预计市场估值是多少？**
A: 针基活检枪市场预计到2035年将达到46.51亿美元的估值。

**Q: 2024年针基活检枪市场的市场估值是多少？**
A: 在2024年，针基活检枪市场的市场估值为21.38亿美元。

**Q: 在2025年至2035年的预测期内，针基活检枪市场的预期CAGR是多少？**
A: 在2025年至2035年的预测期内，基于针的活检枪市场的预期年均增长率（CAGR）为7.32%。

**Q: 在针基活检枪市场中，哪些公司被视为关键参与者？**
A: 针刺活检枪市场的主要参与者包括贝克顿·迪金森公司、波士顿科学公司和美敦力公司等。

**Q: 市场上有哪些不同类型的活检枪？**
A: 市场上有全自动、半自动和手动活检枪，预计到2035年，分别的估值为18.95、14.2和13.36亿美元。

**Q: 医院和诊断实验室在针式活检枪的市场份额方面如何比较？**
A: 到2035年，医院预计将占188.5亿美元，而诊断实验室预计将达到14.4亿美元。

**Q: 对活检枪的一次性和可重复使用产品配置的预期增长是什么？**
A: 一次性活检枪预计将增长至23.05亿美元，而可重复使用的配置预计到2035年将达到23.46亿美元。

**Q: 针基活检枪市场上有哪些针头尺寸可供选择？**
A: 市场提供细规、 中规和大规针，预计到2035年，估值分别为18.85、15.75和11.91亿美元。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/needle-based-biopsy-gun-market-38903*